Current Projects

 

MSDSD Slider2
The Center for Clinical Neurosciences of the University Hospital Carl Gustav Carus at TU Dresden and the Carl Gustav Carus Management GmbH c / o University Hospital Dresden commissioned MedicalSyn with the technical operation and support of the MSDS3D system.

More Information:
Click here
TRUST Slider2
A 3-year, multi-center, prospective, non-interventional study to investigate the impact of integrated patient management including biomarkers, magnetic resonance tomography, and expert advice on disease progression in patients with relapsing forms of multiple sclerosis who have been treated with TYSABRI for at least 12 months.

Study Number:
GER-TYS-14-1062
Sponsor:
Biogen GmbH
More Information:
Click here
MDBS Logo Light
MDBS is a medical database system developed by MedicalSyn. Based on more than 10 years of experience in the development and operation of medical-clinical database solutions MDBS provides a multidimensional documentation of clinical parameters associated with external eHealth-devices and data services (e.g. MRT, laboratory data). Furthermore, it allows users to access the entire data situation of patients locally independent and in real time.

More Information:
Click here
ZEUS Slider2
5-year multi-center, prospective single-cohort non-interventional study documenting the use of Zinbryta® (daclizumab) on patients with relapsing forms of multiple sclerosis (RMS) in clinical practice in Germany.

Study Number:
EUR-ZIN-16-11024

Sponsor:
Biogen GmbH

More Information:
Click here
Coptivity Slider2
COPTIVITY (COPAXONE ACTIVITY STUDY) is a 2-year, open-label, multi-center non-interventional study that evaluates physical and mental activity in patients treated with glatiramer acetate (COPAXONE®) on an outpatient basis. In addition to safety aspects, relapses, and progression of the disease, assessment- and treatment-relevant parameters are acquired, such as disability, fatigue, work ability, quality of life, cognition, and satisfaction with the therapy.

Sponsor:
TEVA GmbH

More Information:
Click here
MSPAths Slider2
MS PATHS stands for Multiple Sclerosis Partners Advancing Technology and Health Solutions. MS PATHS uses advances in technology to generate and collect standardized patient data during routine office visits. Information gathered from patients at participating MS centers will enable research that could potentially lead to new discoveries in MS.

Study Code of Substudy:
888MS001

Sponsor:
Biogen

More Information:
Click here
Pangaea1 Slider2
PANGAEA (Post-Authorization Non-interventional German sAfety of GilEnyA in RRMS patients), a prospective, multicenter, non-interventional, long-term study to collect safety, efficacy, and pharmacoeconomic data on RRMS patients treated with fingolimod (0.5 mg/daily) under real-world conditions in Germany.

Study Number:
CFTY720DDE02

Sponsor:
Novartis Pharma GmbH

More Information:
Click here
Pangaea2 Slider2
PANGAEA 2.0 (Post-Authorization Non-interventional GermAn treatment benefit study of GilEnyA in MS patients), a non-interventional study on patients with relapsing-remitting MS (RRMS) to identify patients with disease activity and monitor their disease course after treatment switch to fingolimod (Gilenya®), an oral medication approved for patients with highly active RRMS.

Study Number:
CFTY720DDE26
Sponsor:
Novartis Pharma GmbH
More Information:
Click here
Lemtrada Slider2
TREAT-MS is a non-interventional long-term study to monitor LEMTRADA® therapy in active, relapsing-remitting MS. In this study, the effects of humanized monoclonal IgG 1K antibody therapy on MS-related parameters, such as relapse rate and disability level, as well as patient-relevant parameters, such as cognition, quality of life, and work ability, will be assessed in approximately 3200 RRMS patients examined and recorded from 400 centers in Germany.

Study Number:
ALEMTL07122
Sponsor:
Genzyme GmbH
More Information:
Click here

We use cookies to offer you the best possible service. By continuing to use our services, you consent to the use of cookies in accordance with our Privacy Policy.
More information Ok Decline